Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 29

  • The following term was not found in PubMed: Context%3A.
1.

Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.

Capoulade R, Yeang C, Chan KL, Pibarot P, Tsimikas S.

JAMA Cardiol. 2018 Nov 21. doi: 10.1001/jamacardio.2018.3798. [Epub ahead of print]

PMID:
30476957
2.

Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins.

Fazio S, Minnier J, Shapiro MD, Tsimikas S, Tarugi P, Averna MR, Arca M, Tavori H.

J Clin Endocrinol Metab. 2017 Sep 1;102(9):3340-3348. doi: 10.1210/jc.2016-4043.

3.

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.

Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S.

N Engl J Med. 2017 Jul 20;377(3):222-232. doi: 10.1056/NEJMoa1701329. Epub 2017 May 24.

4.

Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis.

Saleheen D, Haycock PC, Zhao W, Rasheed A, Taleb A, Imran A, Abbas S, Majeed F, Akhtar S, Qamar N, Zaman KS, Yaqoob Z, Saghir T, Rizvi SNH, Memon A, Mallick NH, Ishaq M, Rasheed SZ, Memon FU, Mahmood K, Ahmed N, Frossard P, Tsimikas S, Witztum JL, Marcovina S, Sandhu M, Rader DJ, Danesh J.

Lancet Diabetes Endocrinol. 2017 Jul;5(7):524-533. doi: 10.1016/S2213-8587(17)30088-8. Epub 2017 Apr 10. Erratum in: Lancet Diabetes Endocrinol. 2017 Sep;5(9):e6.

5.

A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.

Tsimikas S.

J Am Coll Cardiol. 2017 Feb 14;69(6):692-711. doi: 10.1016/j.jacc.2016.11.042. Review.

6.

Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack.

Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; SPARCL Trial Investigators.

J Am Coll Cardiol. 2017 Jan 17;69(2):147-158. doi: 10.1016/j.jacc.2016.10.057.

7.

Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk.

Yeang C, Clopton PC, Tsimikas S.

J Clin Lipidol. 2016 Nov - Dec;10(6):1389-1396. doi: 10.1016/j.jacl.2016.09.012. Epub 2016 Sep 28.

PMID:
27919356
8.

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.

Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.

Lancet. 2016 Nov 5;388(10057):2239-2253. doi: 10.1016/S0140-6736(16)31009-1. Epub 2016 Sep 21.

PMID:
27665230
9.

Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia.

Duell PB, Santos RD, Kirwan BA, Witztum JL, Tsimikas S, Kastelein JJP.

J Clin Lipidol. 2016 Jul-Aug;10(4):1011-1021. doi: 10.1016/j.jacl.2016.04.013. Epub 2016 May 9.

PMID:
27578134
10.

Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.

Yeang C, Cotter B, Tsimikas S.

Cardiovasc Drugs Ther. 2016 Feb;30(1):75-85. doi: 10.1007/s10557-015-6634-1. Review.

PMID:
26780907
11.
12.

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study.

Tsimikas S, Viney NJ, Hughes SG, Singleton W, Graham MJ, Baker BF, Burkey JL, Yang Q, Marcovina SM, Geary RS, Crooke RM, Witztum JL.

Lancet. 2015 Oct 10;386(10002):1472-83. doi: 10.1016/S0140-6736(15)61252-1. Epub 2015 Jul 22.

PMID:
26210642
13.

What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?

Hung MY, Tsimikas S.

Curr Opin Lipidol. 2014 Dec;25(6):423-30. doi: 10.1097/MOL.0000000000000131. Review.

PMID:
25340480
14.

The association between circulating lipoprotein(a) and type 2 diabetes: is it causal?

Ye Z, Haycock PC, Gurdasani D, Pomilla C, Boekholdt SM, Tsimikas S, Khaw KT, Wareham NJ, Sandhu MS, Forouhi NG.

Diabetes. 2014 Jan;63(1):332-342. doi: 10.2337/db13-1144. Epub 2013 Oct 2.

15.

Statin therapy and secretory phospholipase A₂ in children with heterozygous familial hypercholesterolemia.

Braamskamp MJ, Tsimikas S, Wiegman A, Kastelein JJ, Hutten BA.

Atherosclerosis. 2013 Aug;229(2):404-7. doi: 10.1016/j.atherosclerosis.2013.05.023. Epub 2013 Jun 14.

PMID:
23880195
16.

Emerging therapeutic agents to lower lipoprotein (a) levels.

Kolski B, Tsimikas S.

Curr Opin Lipidol. 2012 Dec;23(6):560-8. doi: 10.1097/MOL.0b013e3283598d81. Review.

PMID:
23041907
17.

Regression of inflammation in atherosclerosis by the LXR agonist R211945: a noninvasive assessment and comparison with atorvastatin.

Vucic E, Calcagno C, Dickson SD, Rudd JH, Hayashi K, Bucerius J, Moshier E, Mounessa JS, Roytman M, Moon MJ, Lin J, Ramachandran S, Tanimoto T, Brown K, Kotsuma M, Tsimikas S, Fisher EA, Nicolay K, Fuster V, Fayad ZA.

JACC Cardiovasc Imaging. 2012 Aug;5(8):819-28. doi: 10.1016/j.jcmg.2011.11.025.

18.

Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.

Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S; Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Trial Investigators.

Circulation. 2012 Feb 14;125(6):757-66. doi: 10.1161/CIRCULATIONAHA.111.063487. Epub 2012 Jan 9.

PMID:
22230483
19.

Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression.

Tsimikas S, Miyanohara A, Hartvigsen K, Merki E, Shaw PX, Chou MY, Pattison J, Torzewski M, Sollors J, Friedmann T, Lai NC, Hammond HK, Getz GS, Reardon CA, Li AC, Banka CL, Witztum JL.

J Am Coll Cardiol. 2011 Oct 11;58(16):1715-27. doi: 10.1016/j.jacc.2011.07.017.

20.

Peer-led diabetes education programs in high-risk Mexican Americans improve glycemic control compared with standard approaches: a Project Dulce promotora randomized trial.

Philis-Tsimikas A, Fortmann A, Lleva-Ocana L, Walker C, Gallo LC.

Diabetes Care. 2011 Sep;34(9):1926-31. doi: 10.2337/dc10-2081. Epub 2011 Jul 20.

Supplemental Content

Loading ...
Support Center